Sulfotransferase family 6B member 1 (SULT6B1)

Sulfotransferase family 6B member 1 (SULT6B1) is a cytosolic enzyme in humans that catalyzes sulfate conjugation (sulfation) reactions, specifically utilizing 3'-phosphoadenosine-5'-phosphosulfate (PAPS) as a sulfonate donor to transfer a sulfate group to the thyroid hormone thyroxine[4][1]. This enzyme is part of the broader cytosolic sulfotransferase (SULT) family, which participates in phase II metabolism of both endogenous hormones and xenobiotic compounds[7][1][4]. SULT6B1 has been functionally characterized at the enzymatic level in recombinant model systems, but structural studies reveal that it lacks the typical N-terminal β-sheet seen in other SULTs and is challenging to express using bacterial systems[2][3]. Genetic and pathway data associate SULT6B1 chiefly with thyroxine metabolism, and while predicted to be cytosolic, its detailed physiological substrate specificity and clinical importance are still developing. Disease association is limited, though mutations have been linked with partial motor epilepsy[4]. Notes/limitations: - There are currently no widely documented drugs, mechanisms of drug action, biomarkers, or safety concerns reported for SULT6B1 in the literature as of the latest available data[4][1][2]. - SULT6B1 is not a major, established drug target in current pharmaceutical pipelines. Sources: [1][2][3][4][7]

Other names

Sulfotransferase 6B1SULT6B1ST6B1Thyroxine sulfotransferasesulfotransferase family, cytosolic, 6B, member 1